eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer® (SU2C) Canada

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first breast cancer patient has been dosed with a combination of tomivosertib and paclitaxel in a Phase 2 study led by McGill University in Canada.

eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities

SAN DIEGO, OCTOBER 26, 2020 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that data presented over the weekend at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA 2020)

eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO, Oct. 15, 2020 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Premal Patel, M.D., Ph.D., as chief medical officer.

eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors

SAN DIEGO, MAY 29, 2020 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that positive Phase 2 data from its pipeline program tomivosertib (eFT508)

eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Study Reported in Peer-Reviewed Journal Nature

SAN DIEGO, April 30, 2020 – eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate zotatifin (eFT226) had in vitro antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The results of the research

eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types in Preclinical Models of Disease

SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced that data presented today in a virtual session at the AACR Annual Meeting,

eFFECTOR to Present During BIO CEO & Investor Conference

San Diego, February 6, 2020—eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 11 at 2:00 p.m. ET. The conference will take place February 10-11, in New York, N.Y.

eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, and Pfizer Inc. (NYSE: PFE) today announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E), a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways. eIF4E is an effector protein that is activated in a variety of human cancers and is linked to poor prognosis and resistance to certain therapies.

eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies

SAN DIEGO, November 5, 2019 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the dosing of the first subject in the phase 1/2 study of zotatifin (eFT226) being developed for advanced solid tumor malignancies. Zotatifin is a novel, potent and selective small molecule inhibitor of eukaryotic initiation factor 4A (eIF4A).

eFFECTOR Presents Data on its Selective Translation Regulators at AACR 2019 Annual Meeting

SAN DIEGO, MARCH 29, 2019 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that data from all three of its pipeline programs – tomivosertib, eFT226 and its eIF4E program – will be presented at the AACR 2019 Annual Meeting in Atlanta, occurring March 29 through April 3.